Corcoran Andrea 4

What Happened
Andrea Corcoran, Atea Pharmaceuticals' Chief Financial Officer (also Executive VP, Legal & Secretary), had multiple equity transactions on January 31, 2026. She was granted/received 180,000 restricted stock units (RSUs). On the same date she had derivative exercises/conversions totaling 54,866 shares acquired and several derivative conversions/reported dispositions of 44,366 and 10,500 shares. To cover tax obligations, 16,104 shares were surrendered/withheld at $4.24 per share, totaling $68,281. The filing shows these events as exercises/conversions and an award/grant of RSUs rather than an open-market purchase or sale.

Key Details

• Transaction date: January 31, 2026; Form 4 filed February 3, 2026.
• Tax withholding: 16,104 shares disposed at $4.24/share for $68,281 (code F).
• Derivative activity: 54,866 shares acquired via exercise/conversion (code M); additional derivative conversions/dispositions of 44,366 and 10,500 shares (reported at $0).
• Award: 180,000 RSUs granted/reported as acquired (code A). Each RSU equals a contingent right to one share (footnote).
• Footnotes of note: original grant of 133,100 RSUs fully vested as of Jan 31, 2026 (F3); performance RSUs vested on Jan 31, 2026 (F4); includes 7,507 shares from the 2020 ESPP (F2). An option referenced will vest monthly after Jan 31, 2026 and fully vest Jan 31, 2030 (F5).
• Shares owned after the transactions: not specified in the provided filing summary.

Context
These entries reflect equity compensation events (RSU vesting and derivative exercises/conversions) and a tax-withholding share surrender—not an open-market sale or purchase for investment. The tax withholding (net share settlement) is common when RSUs vest or options are exercised. The newly reported 180,000 RSUs and the vesting of prior RSUs increase the executive’s equity stake subject to the plan and vesting terms; an option noted in the filing will vest over the next four years.